KDM6A and acute myeloid leukemia: These findings indicate that KDM6A confers upon AML cells sensitivity to chemotherapeutic agents and that inhibition of KDM6A with GSK-J4 in AML patients on chemotherapy might facilitate the emergence of resistant clones during relapse [25].